Literature DB >> 18653737

Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study.

B Brochet1, M S A Deloire, M Bonnet, E Salort-Campana, J C Ouallet, K G Petry, V Dousset.   

Abstract

BACKGROUND: The multiple sclerosis functional composite (MSFC) includes the Paced Auditory Serial Addition test (PASAT) as a measure of cognition. OBJECTIVES AND METHODS: We compared the MSFC incorporating the Symbol Digit Modalities test (SDMT) (MSFC [sdmt]) to the usually applied MSFC (MSFC [pasat]) in a sample of 46 ptients with relapsing-remitting MS who were followed over a five-year period. Magnetic resonance imaging was performed at baseline.
RESULTS: The Expanded Disability Status scale (EDSS) deteriorated significantly over 5 years (P < 0.01), but MSFC scores remained stable. MSFC [sdmt] correlated with EDSS at all time points of evaluation, but MSFC [pasat] correlated with EDSS only at baseline, 1, and 5 years. The 5-year EDSS correlated significantly with baseline MSFC [sdmt] and MSFC [pasat] but did not correlate after adjustment for baseline EDSS. No significant correlation was found at baseline between MSFC and imaging parameters (lesion load, brain parenchymal fraction [BPF], ventricular fraction, mean magnetization transfer ratio of lesions and normal-appearing brain tissue), but baseline BPF correlated significantly with changes of SDMT z score (P = 0.0003), MSFC [pasat] (P = 0.006), and MSFC [sdmt] (P = 0.0002) over 5 years.
CONCLUSION: We propose not to substitute PASAT by SDMT in the MSFC but to consider SDMT as a complementary useful approach to evaluate overall MS disease.

Entities:  

Mesh:

Year:  2008        PMID: 18653737     DOI: 10.1177/1352458508094398

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  24 in total

Review 1.  Secondary Progressive Multiple Sclerosis: Definition and Measurement.

Authors:  Domenico Plantone; Floriana De Angelis; Anisha Doshi; Jeremy Chataway
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

2.  The computer-based Symbol Digit Modalities Test: establishing age-expected performance in healthy controls and evaluation of pediatric MS patients.

Authors:  Sandra Bigi; R A Marrie; C Till; E A Yeh; N Akbar; A Feinstein; B L Banwell
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

3.  Possible clinical outcome measures for clinical trials in patients with multiple sclerosis.

Authors:  Myla D Goldman; Robert W Motl; Richard A Rudick
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

4.  Anxiety state affects information processing speed in patients with multiple sclerosis.

Authors:  Benedetta Goretti; R G Viterbo; E Portaccio; C Niccolai; B Hakiki; E Piscolla; P Iaffaldano; M Trojano; M P Amato
Journal:  Neurol Sci       Date:  2013-09-27       Impact factor: 3.307

5.  Effects of acute relapses on neuropsychological status in multiple sclerosis patients.

Authors:  S A Morrow; S Jurgensen; F Forrestal; Frederick E Munchauer; R H B Benedict
Journal:  J Neurol       Date:  2011-03-08       Impact factor: 4.849

Review 6.  Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.

Authors:  Daniel Ontaneda; Robert J Fox; Jeremy Chataway
Journal:  Lancet Neurol       Date:  2015-02       Impact factor: 44.182

7.  Binocular low-contrast letter acuity and the symbol digit modalities test improve the ability of the Multiple Sclerosis Functional Composite to predict disease in pediatric multiple sclerosis.

Authors:  Amy T Waldman; Salim Chahin; Amy M Lavery; Geraldine Liu; Brenda L Banwell; Grant T Liu; Laura J Balcer
Journal:  Mult Scler Relat Disord       Date:  2016-08-26       Impact factor: 4.339

8.  Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study.

Authors:  Sarah A Morrow; Audrey Smerbeck; Kara Patrick; Diane Cookfair; Bianca Weinstock-Guttman; Ralph H B Benedict
Journal:  J Neurol       Date:  2012-09-23       Impact factor: 4.849

Review 9.  Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview.

Authors:  Floriana De Angelis; Domenico Plantone; Jeremy Chataway
Journal:  CNS Drugs       Date:  2018-06       Impact factor: 5.749

10.  Social cognition in pediatric-onset multiple sclerosis (MS).

Authors:  L E Charvet; R E Cleary; K Vazquez; A L Belman; L B Krupp
Journal:  Mult Scler       Date:  2014-03-19       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.